Abiomed (ABMD) Posts Q4 GAAP EPS of $2.24

Abiomed (NASDAQ: ABMD) reported Q4 EPS of $2.24, which may not compare with the analyst estimate of $0.14. Revenue for the quarter came in at $67.6 million versus the consensus estimate of $62.55 million.

Fiscal fourth quarter GAAP income from operations totaled $12.4 million, up 235% compared to $3.7 million in the prior year. GAAP net income included an income tax benefit of $86.5 million largely due to the release of the valuation allowance on most of Abiomed's deferred tax assets. The release of the valuation allowance is a onetime accounting adjustment with the offset recorded on the balance sheet as short and long term deferred tax assets based on the Company's estimates of sustainable profitability.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c